{
  "id": "bad-blood-book",
  "title": "Bad Blood: Secrets and Lies in a Silicon Valley Startup",
  "lang": "en",
  "source_lang": "en",
  "summary": "John Carreyrou’s 2018 nonfiction book investigates Theranos, its blood-testing claims, and the corporate practices that enabled its rise.",
  "category": "economics",
  "subcategory": "business",
  "type": "work",
  "aliases": [
    "Bad Blood"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/bad-blood-book/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/bad-blood-book/",
      "json": "https://aiwiki.page/zh/bad-blood-book.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Bad Blood: Secrets and Lies in a Silicon Valley Startup is a 2018 nonfiction book by investigative journalist John Carreyrou, published by Alfred A. Knopf. It examines the rise of Theranos, the blood-testing company founded by Elizabeth Holmes, and the discrepancy between its public claims and the capabilities of its technology. Expanding on Carreyrou’s reporting for The Wall Street Journal, the book combines a chronological business history with an account of the investigation that brought the company’s practices under public scrutiny."
    },
    {
      "heading": "Subject and background",
      "text": "Theranos proposed to make laboratory testing faster, cheaper, and less invasive by performing numerous tests on very small blood samples, often collected through a finger prick. Its commercial appeal rested on the claim that proprietary technology could replace much of the equipment and blood volume required by conventional laboratory testing.\n\nHolmes founded the company in 2003 after leaving Stanford University. Theranos subsequently attracted prominent investors, board members, and commercial partners. At its peak, private investment valued the business at approximately $9 billion. This valuation reflected investors’ expectations, not independently demonstrated commercial or scientific performance.\n\nThe book follows the development of Theranos’s technology and its efforts to turn an ambitious technical proposition into a consumer-facing service. A central episode is its partnership with Walgreens, through which Theranos offered testing at retail locations. Carreyrou describes how public expansion proceeded despite unresolved technical and laboratory problems."
    },
    {
      "heading": "Contents and narrative structure",
      "text": "The early chapters reconstruct Theranos’s formation, Holmes’s fundraising, the recruitment of employees, and the development of successive testing devices. Later chapters examine the company’s relationship with commercial partners and the management practices of Holmes and company president Ramesh “Sunny” Balwani.\n\nA recurring distinction is between Theranos’s proprietary devices and conventional laboratory analyzers. Carreyrou reports that the company relied extensively on commercial equipment while promoting the capabilities of its own technology. His account also describes problems involving sample preparation, quality control, and the reliability of some test results. The significance of these issues extended beyond business performance because laboratory results inform medical diagnosis and treatment decisions.\n\nThe final portion shifts toward the reporting process. It recounts how employees and former employees provided information, how Carreyrou investigated their accounts, and how Theranos sought to prevent publication. The first major Wall Street Journal investigation appeared in October 2015; the book supplies a broader history and additional reporting around those revelations."
    },
    {
      "heading": "Reporting and principal figures",
      "text": "The book draws on interviews, documents, correspondence, and accounts from people who worked with or investigated Theranos. Its method is that of investigative journalism rather than an academic experiment or a judicial finding: it reconstructs events, compares claims with evidence, and presents a documented narrative.\n\nFormer employees occupy an important place in this account. Erika Cheung and Tyler Shultz are among those whose concerns about laboratory practices and willingness to communicate with outsiders helped expose problems. Their experiences illustrate the practical difficulties facing employees who challenge their organization, including confidentiality obligations, legal pressure, and conflicts of personal loyalty.\n\nCarreyrou also describes Theranos’s attempts to contest his reporting and pressure sources. These episodes make the production of the investigation part of the book’s subject, rather than treating journalism only as the means by which the story became public."
    },
    {
      "heading": "Business and institutional themes",
      "text": "Information asymmetry and verification\n\nThe Theranos case illustrates information asymmetry between company insiders and outside investors, partners, patients, and journalists. Assessing a medical technology requires specialized knowledge and access to reliable performance data. Corporate secrecy restricted that access.\n\nThe book distinguishes persuasive demonstrations and endorsements from independent technical validation. A prestigious board, a prominent investor, or a large commercial partnership could enhance credibility without establishing that the underlying testing system performed as represented.\n\nGovernance and organizational control\n\nThe narrative raises questions about corporate governance, particularly the ability of boards and investors to scrutinize technically complex businesses. It describes an organization in which decision-making was concentrated and employees’ access to information was compartmentalized.\n\nSuch arrangements matter because internal criticism can provide an early warning of technical or operational failure. In Carreyrou’s account, secrecy and pressure on dissenting employees impeded the circulation and correction of adverse information.\n\nInnovation, secrecy, and healthcare\n\nTheranos presented itself through the language of disruptive innovation and rapid growth associated with Silicon Valley entrepreneurship. The book explores the tension between that business culture and the evidentiary requirements of medical testing.\n\nProtecting intellectual property and pursuing ambitious research are normal business activities. They are nevertheless distinct from demonstrating that a clinical service is accurate and reliable. Bad Blood focuses on how these distinctions became obscured in Theranos’s dealings with outsiders."
    },
    {
      "heading": "Publication and reception",
      "text": "Published in May 2018, Bad Blood became a commercial bestseller and won the 2018 Financial Times and McKinsey Business Book of the Year Award. Its reception extended beyond business publishing to discussions of technology companies, healthcare oversight, organizational ethics, and whistleblowing.\n\nThe book’s publication preceded the later criminal trials of Holmes and Balwani. It should therefore be distinguished from a retrospective account of the complete legal proceedings: its central contribution is the reconstruction of Theranos’s rise and the investigation that challenged its claims."
    },
    {
      "heading": "Scope and interpretation",
      "text": "Bad Blood is a closely reported account of a particular company, not a systematic study of all technology startups or venture capital investment. Its case supports examination of specific failures in verification, oversight, and organizational accountability, but does not by itself establish how frequently those failures occur across an industry.\n\nIts narrative emphasis is on discrepancies, warning signs, and the obstacles encountered by those who questioned the company. Statements reconstructed from interviews remain part of a journalistic account; they are not interchangeable with contemporaneous documents, independently reproduced laboratory evidence, or findings reached in subsequent court proceedings."
    }
  ],
  "links": [
    "john-carreyrou",
    "theranos",
    "elizabeth-holmes",
    "ramesh-balwani",
    "diagnosis",
    "investigative-journalism",
    "information-asymmetry",
    "innovation",
    "entrepreneurship",
    "intellectual-property"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}